Wide Ranks

IMMP

Immutep Limited

1.99

Top Statistics
Market Cap 291 M Forward PE -8.87 Revenue Growth -4.90 %
Current Ratio 18.25 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -60.85 Enterprise / Revenue 705.49 Price To Sales Trailing12 Months 75.99
Profitability
Profit Margins 0.00 % Operating Margins -1353.42 %
Balance Sheet
Total Cash 181 M Total Cash Per Share 0.1250 Total Debt 1 M
Total Debt To Equity 0.8410 Current Ratio 18.25 Book Value Per Share 0.1300
All Measures
Short Ratio 5139.00 % Message Board Id finmb_6701589 Fax 61 2 8569 1880
Shares Short Prior Month 4 M Return On Equity -0.2621 City Sydney
Uuid c6d72204-94f0-3b31-acc4-15ee84e34cde Previous Close 1.91 First Trade Date Epoch Utc 1 B
Book Value 0.1300 Beta 1.92 Total Debt 1 M
Volume 73988 Price To Book 15.31 Last Split Date 1 B
Fifty Two Week Low 1.66 Total Cash Per Share 0.1250 Total Revenue 3 M
Shares Short Previous Month Date 1 B Target Median Price 9.50 Max Age 86400
Recommendation Mean 1.50 Sand P52 Week Change 0.3133 Operating Margins -1353.42 %
Target Mean Price 9.50 Net Income To Common -42716624 Short Percent Of Float 0.0360
Implied Shares Outstanding 89 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 154130 Average Volume10days 154130 Total Cash 181 M
Next Fiscal Year End 1 B Revenue Per Share 0.0300 Held Percent Insiders 0.0001
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 1.91 Target Low Price 7.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 2.01 Open 1.95 Free Cashflow -23252288
State NSW Dividend Yield 0.00 % Return On Assets -0.1667
Time Zone Short Name EST Trailing Eps -0.2400 Day Low 1.92
Address1 Australia Square Shares Outstanding 145 M Price Hint 4
Target High Price 12.00 Website https://www.immutep.com Average Volume 113721
Forward Eps -0.2700 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 1806.50 % Last Split Factor 3:10 Regular Market Day High 2.05
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 0.8410
Fifty Two Week High 3.34 Day High 2.05 Shares Short 5 M
Regular Market Open 1.95 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 705.49 Revenue Growth -4.90 % Shares Percent Shares Out 0.0353
Operating Cashflow -34821228 Currency USD Time Zone Full Name America/New_York
Market Cap 291 M Is_nasdaq_100 False Zip 2000
Quote Type EQUITY Industry Biotechnology Long Name Immutep Limited
Regular Market Day Low 1.92 Held Percent Institutions 0.0628 Current Price 1.99
Address2 Level 32 264 George Street Enterprise To Ebitda -60.85 Financial Currency AUD
Current Ratio 18.25 Industry Disp Biotechnology Number Of Analyst Opinions 2
Country Australia Float Shares 1 B Two Hundred Day Average 2.34
Ir Website http://www.primabiomed.com.au/investor/ Enterprise Value 2 B Price To Sales Trailing12 Months 75.99
Forward PE -8.87 Regular Market Volume 73988 Ebitda -44544368
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Immutep Limited, a late-stage biotechnology company, engages in developing novel LAG-3 related immunotherapies for cancer and autoimmune diseases in Australia.

Its lead product candidate is the eftilagimod alpha (efti or IMP321), a soluble LAG-3lg fusion based, which is in clinical development for the treatment of different types of cancers.

The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.

In addition, it develops INSIGHT-003, which is in phase I to treat 1L NSCLC and solid tumors; INSIGHT-005, which is in phase I to treat metastatic urothelial cancer; IMP761, which is in preclinical trial to treat autoimmune disease; and IMP731 and IMP701 which is in clinical development.

Further, the company develops LAG525, which is in phase II clinical trial to treat solid tumors and blood cancer, triple negative breast cancer, and melanoma; and in phase I to treat triple negative breast cancer.

Immutep has collaboration with Merck & Co.

, Inc., GlaxoSmithKline, EOC Pharma, Novartis, and Laboratory Corporation of America Holdings.

The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017.

The company was incorporated in 1987 and is based in Sydney, Australia.